.jpeg)
{{ variable.name }}
Aprocitentan is an endothelin receptor antagonist (ERA) used to treat hypertension, particularly in combination with other antihypertensive medications, to lower blood pressure in adult patients whose blood pressure is not adequately controlled despite other medications.
1. Generic name: Aprocitentan (Aprocitentan)
2. Trade name: TRYVIO™
is used to treat high blood pressure and needs to be used in combination with other antihypertensive drugs. It is suitable for adult patients to lower blood pressure when other drugs are not well controlled. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, such as stroke and myocardial infarction.
1. Specifications: 12.5mg/tablet.
2. Properties: film-coated tablets.
1. Active ingredient: aprecitentan
2. Excipients: croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, etc.
1. Recommended dosage: 12.5mg orally taken once a day, with food or on an empty stomach.
2. Treatment of missed doses: skip the missed dose and take the medicine at the original time next time. Do not take a double dose on the same day.
1. People who do not need to adjust the dose: elderly people over 65 years old, mild to severe renal insufficiency (eGFR≥15mL/min), mild liver injury (Child-Pugh A grade).
2. People who are prohibited or used with caution: patients with renal failure (eGFR<15mL/min) or dialysis, moderate to severe liver injury (Child-Pugh B/C grade).
1. Pregnancy contraindications : Contraindicated in pregnant women. Pregnancy negative must be confirmed before taking the medication. Pregnancy monitoring needs to be monitored monthly during treatment and within 1 month after stopping the medication.
2. Contraceptive requirements : Patients of childbearing age need to take effective contraceptive measures before taking the medication, during the medication and within 1 month after stopping the medication.
3. Influence of diet : not affected by food.
4. Vomiting treatment : If you vomit after taking the medicine, there is no need to take a supplement, just take the next dose as originally planned.
1. Pregnant women: is absolutely contraindicated and may cause fetal malformations.
2. During lactation : It is recommended to stop taking the medicine or stop breastfeeding.
3. Children’s : Safety and effectiveness have not been established.
4. Elderly people : are more prone to edema/fluid retention and need to be closely monitored.
1. Common (≥2%): edema/fluid retention (9.1%), anemia (3.7%).
2. Serious risks: liver toxicity, decreased hemoglobin, decreased sperm count.
1. Pregnancy.
2. Are allergic to aprecitentan or any excipients.
1. UGT inducer (such as rifampicin): may reduce the plasma concentration of aprecitentan.
2. CYP3A4/CYP2C family inhibitor : caution should be used in combination.
3. There is no significant interaction with midazolam (CYP3A4 substrate) and rosuvastatin (BCRP substrate).
Save at 20°C–25°C (15°C–30°C fluctuation allowed). Protect from light and moisture in the original packaging. Keep the desiccant after opening.